Our research
The field of pharmacoepidemiology emerged as a research subject in the early 1960s following the drug disaster surrounding the medication thalidomide (Neurosedyn) and alarm reports regarding quality deficiencies and high costs of pharmaceuticals within healthcare.
Since then, there has been rapid development. Today, the subject encompasses analyses of how medications are prescribed and used, as well as studies on the benefits and side effects of drug treatment. With increasingly sophisticated medications being studied on fewer individuals when they enter the market, rising drug usage, and an increased focus on sustainable pharmaceutical use socially, economically, and ecologically, pharmacoepidemiology is a rapidly expanding research area. More about pharmacoepidemiology and its future can be read in an issue of SVEPET (2019 No. 4) and the article 'Intriguing Future of Pharmacoepidemiology' (National Library of Medicine).
Our main research areas
Medication adherence
Our research is about medication adherence in different diseases, the factors influencing adherence, and how one can improve adherence, including through digital solutions.
Cardiovascular diseases and diabetes
Our research on cardiovascular diseases and diabetes focuses on how medications are prescribed and used. The aim is to improve medication usage so that fewer people experience premature death and reduced quality of life.
Pharmaceuticals in the environment
Pharmaceuticals in the environment can affect fish and aquatic animals, thus impacting entire ecosystems. Our research group is dedicated to studying how to analyze and prevent the negative effects of pharmaceuticals on the environment.
